➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
McKesson
Express Scripts
AstraZeneca
Harvard Business School

Last Updated: July 3, 2020

DrugPatentWatch Database Preview

NUPRIN Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which patents cover Nuprin, and what generic alternatives are available?

Nuprin is a drug marketed by Bristol Myers and J And J Consumer Inc and is included in three NDAs.

The generic ingredient in NUPRIN is ibuprofen. There are sixty-four drug master file entries for this compound. Two hundred and twenty-two suppliers are listed for this compound. Additional details are available on the ibuprofen profile page.

US ANDA Litigation and Generic Entry Outlook for Nuprin

A generic version of NUPRIN was approved as ibuprofen by OHM on July 15th, 1986.

  Start Trial

Drug patent expirations by year for NUPRIN
Recent Clinical Trials for NUPRIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Haining Health-Coming Biotech Co., Ltd.Phase 2
National Institutes of Health Clinical Center (CC)Phase 1
National Institute of Dental and Craniofacial Research (NIDCR)Phase 2

See all NUPRIN clinical trials

US Patents and Regulatory Information for NUPRIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers NUPRIN ibuprofen TABLET;ORAL 072035-001 Feb 16, 1988 DISCN No No   Start Trial   Start Trial   Start Trial
J And J Consumer Inc NUPRIN ibuprofen TABLET;ORAL 019012-002 Jul 29, 1987 DISCN No No   Start Trial   Start Trial   Start Trial
Bristol Myers NUPRIN ibuprofen TABLET;ORAL 072036-001 Feb 16, 1988 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
McKesson
Express Scripts
AstraZeneca
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.